Thrombocytopenia chemotherapy-related

F. Role in therapy According to Micro-medex, treatment of severe chemotherapy-related thrombocytopenia is hmited to platelet transfusions. There is a need for an alternative, especially due to the frequent use of myeloid colony-stimulating factors (G-CSF, GM-CSF) to reduce febrile neutropenia although effective, their use increases the risk of acute and prolonged thrombocytopenia, and the need for platelet transfusions. Other cytokines, such as interleukin-1 and interleukin-6, have been investigated as a means of ameliorating chemotherapy-induced thrombocytopenia, but results have been equivocal. 

Persistent or recurrent cutaneous T-cell lymphoma Prevention of severe chemotherapy-induced thrombocytopenia Moderate to severe active rheumatoid arthritis Moderate to severe active rheumatoid arthritis Anemia related to AZT therapy in HIV-infected patients Anemia associated with chronic renal failure... 

Bevacizumab has been studied in advanced carcinoid tumors [167 ], prostate cancer [168 ], high-risk corneal transplantation [169 ], diabetic retinopathy [170 , 171, 172 ], ischemic retinal diseases [173 ], refractory choroidal neovascularization secondary to uveitis [174 ], macular edema secondary to branch retinal vein occlusion [175 ], retinal angiomatous proliferation [176% choroidal neovascularization attributable to pathological myopia [177, 178], exudative age-related macular degeneration [179 ], multifocal lymphangioendothe-liomatosis with thrombocytopenia [180" ], in combination with chemotherapy for the treatment of recurrent ovarian cancer [181 j, advanced melanoma [182 ], malignant pleural mesothelioma [183 ],... 

---